On August 26, 2020 Sinovent, a Suzhou clinical stage biologics company, reported that it raised $145 million in a Series C round led by Loyal Valley Innovation Capital (Press release, Sinovent, AUG 26, 2020, View Source [SID1234564084]). The company has 12 biologic products in development, four in clinical trials and another four molecules preparing to file INDs in China. Sinovent’s lead program is a Wnt pathway porcupine inhibitor aimed at cancers of the digestive system, including colon cancer, esophageal cancer and gastric cancer. Founded in 2016, Sinovent’s 12 research pipelines address needs in therapeutic areas that include oncology, central nervous system, autoimmune and infectious diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!